10/3/2023 0 Comments Faqt score 79![]() NHANES III was conducted by the National Center for Health Statistics (NCHS) from 1988 to 1994, using a stratified multistage probability sample that represented the civilian non-institutionalized population in the USA. ![]() In this study, we aimed to validate and evaluate the performance of these non-invasive prediction scores of NAFLD in predicting ultrasonography-diagnosed NAFLD in a representative general adult population in the USA (cross-sectional NAFLD prediction cohort), and to test if the marker can predict mortality in the general population (prospective mortality prediction cohort).ĭata from the third National Health and Nutrition Examination Survey (NHANES III) were used. In addition, whether these non-invasive scores of NAFLD can predict clinical outcome remains largely unknown. However, different definitions and techniques were used to define NAFLD in the original studies, and the performances of these scores have not been validated, evaluated, and compared directly in a large general population. These scores are derived from simple clinical risk factors and biomarkers, and can therefore potentially be used for large-scale NAFLD screening. Recently, five biomarker-based non-invasive prediction scores of NAFLD have been developed: SteatoTest, fatty liver index (FLI), NAFLD liver fat score (LFS), lipid accumulation product (LAP), and hepatic steatosis index (HSI). However, these tools are expensive and time-consuming, and are not considered cost-effective for large-scale NAFLD screening. Other non-invasive tools have been developed for diagnosing NAFLD, such as computed tomography and proton magnetic resonance spectroscopy ( 1H-MRS). ![]() Ultrasonography is therefore the recommended first-line imaging technique in clinical practice, although it is known to have limited sensitivity. Liver biopsy remains the “gold standard” for NAFLD diagnosis however, this is an invasive technique making it impractical to be used widely. As NAFLD is highly prevalent and affects up to 30% of the general adult population, screening for and diagnosing NAFLD has become an important issue in public health to prevent NAFLD-related complications and reduce healthcare costs. ![]() NAFLD is regarded as a hepatic manifestation of metabolic syndrome (MetS), therefore the presence of NAFLD is not only strongly associated with liver-related mortality, but also with diseases related to the MetS, such as diabetes and cardiovascular diseases. Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of progressive liver disease ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, in the absence of excessive alcohol consumption. LFS is the best non-invasive prediction score for NAFLD, and people with a high LFS score have an increased risk for cardiovascular and liver-related mortality. Similar results were obtained when LFS was treated as a continuous variable. During a median follow-up of 14.7 years (range 0.1 to 18.2 years) and 83,830.5 person-years, participants in the high LFS group (LFS ≥1.257) had a higher cardiovascular and liver-related mortality than participants in the low (LFS ≤− 1.413 cardiovascular hazard ratio (HR) = 2.24, 95% CI 1.03 to 4.88 liver HR = 31.25, 95% CI 3.13 to 333.33) or intermediate (-1.413 < LFS < 1.257 cardiovascular HR = 2.3, 95% CI 1.19 to 4.48 liver HR = 30.3, 95% CI 4 to 250) LFS groups in the fully adjusted model. In a group of 5,184 participants, LFS consistently showed the highest area under the curve for predicting the presence of NAFLD. NAFLD was defined by ultrasonographic detection of hepatic steatosis in the absence of other known liver diseases. We analyzed data from the National Health and Nutrition Examination Survey conducted in 1988 to 1994, and subsequent follow-up data for mortality up to December 31, 2006. In this study, we aimed to validate and compare the performance of four NAFLD prediction scores: fatty liver index, hepatic steatosis index, lipid accumulation product, and NAFLD liver fat score (LFS), and to evaluate the ability of the best NAFLD prediction score to predict mortality. Several non-invasive prediction scores for non-alcoholic fatty liver disease (NAFLD) have been developed, but their performance has not been compared and validated in the same population, and whether these prediction scores can predict clinical outcomes remains unknown.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |